Senseonics Holdings, Inc. (NYSE:SENS) Receives $22.70 Average PT from Brokerages

Senseonics Holdings, Inc. (NYSE:SENS) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $22.70.

SENS has been the subject of several analyst reports. Barclays reiterated an “overweight” rating and set a $31.00 price objective (up from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. HC Wainwright lifted their target price on Senseonics to $18.50 and gave the company a “buy” rating in a research note on Thursday, November 6th. Stifel Nicolaus started coverage on Senseonics in a research note on Tuesday, October 21st. They issued a “hold” rating and a $9.00 price target for the company. Finally, TD Cowen reissued a “buy” rating on shares of Senseonics in a report on Thursday, January 8th.

Senseonics Stock Performance

Shares of SENS opened at $7.33 on Friday. The firm has a fifty day moving average of $6.58 and a 200-day moving average of $7.98. The company has a market cap of $299.50 million, a price-to-earnings ratio of -56.38 and a beta of 0.63. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. Senseonics has a 1 year low of $5.25 and a 1 year high of $28.00.

Insiders Place Their Bets

In related news, Director Edelman Steven purchased 10,000 shares of Senseonics stock in a transaction dated Monday, November 10th. The stock was bought at an average cost of $6.55 per share, with a total value of $65,500.00. Following the purchase, the director owned 74,708 shares in the company, valued at approximately $489,337.40. The trade was a 15.45% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Douglas A. Roeder acquired 15,000 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were bought at an average price of $5.83 per share, for a total transaction of $87,450.00. Following the purchase, the director directly owned 99,727 shares of the company’s stock, valued at approximately $581,408.41. This trade represents a 17.70% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 30,415 shares of company stock worth $184,790. 3.60% of the stock is owned by corporate insiders.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Maven Securities LTD acquired a new position in Senseonics during the second quarter worth about $129,000. Hood River Capital Management LLC bought a new position in shares of Senseonics during the 2nd quarter valued at about $3,775,000. Sio Capital Management LLC acquired a new position in shares of Senseonics in the 2nd quarter worth approximately $2,312,000. Elite Life Management LLC bought a new stake in shares of Senseonics in the 2nd quarter worth approximately $36,000. Finally, HBK Sorce Advisory LLC acquired a new stake in Senseonics during the third quarter valued at approximately $39,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.